secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062045
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024
--------------------------------------------------------------------------------

- Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.
- Cash, cash equivalents and investments at $172.9M as of Sept 30, down from $245.2M at Dec 31, 2022; operating cash burn $74.5M YTD.
- Phase 2/3 LIFT-AD trial enrollment for fosgonimeton expected complete by Q1 2024; topline data anticipated in H2 2024.
- ATH-1105 (oral ALS candidate) IND-enabling studies ongoing; first-in-human study expected in H1 2024.
- New preclinical fosgonimeton data to be presented at Neuroscience 2023 (Nov 11-15) in Washington, D.C.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/0000950170-23-062045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/atha-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer